Immunohistochemical Evaluation of 95 Bone Marrow Reactive Plasmacytoses

被引：6

作者：

Ioannou, Maria G. ^{[1
]}

Stathakis, Efstathios ^{[1
]}

Lazaris, Andreas C. ^{[1
]}

Papathomas, Thomas ^{[1
]}

Tsiambas, Evangelos ^{[1
]}

Koukoulis, George K. ^{[1
]}

机构：

[1] Univ Thessaly, Sch Med, Dept Pathol, Larisa, Greece

来源：

PATHOLOGY & ONCOLOGY RESEARCH | 2009年 / 15卷 / 01期

关键词：

CD56; Cyclin D1; Immunohistology; Bone marrow biopsies; Reactive plasmacytosis; Plasma cell myeloma; MULTIPLE-MYELOMA; PLASMA-CELLS; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; EXPRESSION; CD56; LESIONS; BIOPSY;

D O I：

10.1007/s12253-008-9069-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We histologically and immunohistochemically studied 95 bone marrow (BM) reactive plasmacytoses. Ten biopsies from plasma cell myeloma (PCM) patients served as a control group. In addition, we studied 10 monoclonal gammopathy of undetermined significance (MGUS) cases. Histologically, plasmacytosis varied between 5% and 25% with an interstitial pattern of plasma cell (PC) distribution being characteristically displayed. Immunohistochemically, we did not find any CD56/NCAM nor cyclin D1 expression in all biopsies (95 of 95, 100%), not even a weak, doubtful one; PCs were all polyclonal and CD138 positive. On the contrary, myeloma-associated PCs showed monoclonality for kappa- or lambda- light chain and strong CD56/NCAM immunoreactivity (8 of 10, 80%); four of them were cyclin D1 positive. Osteoblasts exhibited similar CD56/NCAM expression in both groups. Our data confirm the diagnostic utility of CD56/NCAM in the phenotypic characterization of polyclonal plasma cells, suggesting an important role of this particular immunomarker in the BM trephine study of polyclonal versus neoplastic plasmacytic infiltrations.

引用

页码：25 / 29

页数：5

共 25 条

[1]

Bain BJ., 2001, BONE MARROW PATHOLOG, V3rd

[2]

Bataille R, 2006, HAEMATOLOGICA, V91, P1234

[3]

BRUNNING RD, 2004, ROSAI ACKERMANS SURG, P2099

[4] Bone marrow biopsy: Interpretive guidelines for the surgical pathologist [J].

Cotelingam, JD .

ADVANCES IN ANATOMIC PATHOLOGY, 2003, 10 (01) :8-26

[5] Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma [J].

Dahl, IMS ;

Rasmussen, T ;

Kauric, G ;

Husebekk, A .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) :273-277

[6]

DICK FR, 2002, CLIN LAB MED, P923

[7] Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma [J].

Dunphy, Cherie Hilborn ;

Nies, Melanie Kandt ;

Gabriel, Don Alexander .

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (03) :248-254

[8] Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation [J].

Ely, SA ;

Knowles, DM .

AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (04) :1293-1299

[9] Diagnosis and classification of malignant lymphoma and related entities in the bone marrow trephine biopsy [J].

Fend, Falko ;

Kremer, Markus .

PATHOBIOLOGY, 2007, 74 (02) :133-143

[10]

Grogan TM., 2001, PATHOLOGY GENETICS T, P142

← 1 2 3 →